These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33051307)

  • 1. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
    Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
    Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
    Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
    Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
    O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
    Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarcinoma and correlate with survival outcome.
    Chen Q; Chen Z; Zhang J; Cai Y; Wu S; He D; Cheng K; Gu X; Cai Y; Wang X; Li Y; Zhang M; Wu Z; Peng B
    FASEB J; 2024 Aug; 38(15):e23867. PubMed ID: 39101950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: a systematic review.
    Robertson FP; Cameron A; Spiers HVM; Joseph N; Taylor E; Ratnayake B; Jamieson NB; Pandanaboyana S
    HPB (Oxford); 2024 May; 26(5):609-617. PubMed ID: 38401998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
    Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
    Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
    Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
    Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
    Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
    Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 14. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
    Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
    PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism.
    Ohara Y; Craig AJ; Liu H; Yang S; Moreno P; Dorsey TH; Cawley H; Azizian A; Gaedcke J; Ghadimi M; Hanna N; Ambs S; Hussain SP
    Carcinogenesis; 2024 Jul; 45(7):475-486. PubMed ID: 38366633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer.
    Lee JJ; Kearney JF; Trembath HE; Hariharan A; LaBella ME; Kharitonova EV; Chan PS; Morrison AB; Cliff A; Meyers MO; Kim HJ; Rashid NU; Peng XL; Yeh JJ
    Ann Surg; 2024 Oct; 280(4):659-666. PubMed ID: 38887930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Will molecular diagnostics become established in pancreatic pathology?].
    Sipos B; Sperveslage J
    Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma.
    Salinas-Miranda E; Healy GM; Grünwald B; Jain R; Deniffel D; O'Kane GM; Grant R; Wilson J; Knox J; Gallinger S; Fischer S; Khokha R; Haider MA
    Eur Radiol; 2022 Oct; 32(10):6712-6722. PubMed ID: 36006427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4.
    Camolotto SA; Belova VK; Torre-Healy L; Vahrenkamp JM; Berrett KC; Conway H; Shea J; Stubben C; Moffitt R; Gertz J; Snyder EL
    Gut; 2021 May; 70(5):900-914. PubMed ID: 32826305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.